关注
Indranil Mondal
Indranil Mondal
National Cancer Institute (NCI), National Institutes of Health (NIH)
在 nih.gov 的电子邮件经过验证
标题
引用次数
引用次数
年份
Silver nanoparticles (AgNPs) as a contrast agent for imaging of animal tissue using swept-source optical coherence tomography (SSOCT)
I Mondal, S Raj, P Roy, R Poddar
Laser Physics 28 (1), 015601, 2017
192017
Potential of microRNA based diagnostics and therapeutics in glioma: a patent review
I Mondal, R Kulshreshtha
Expert Opinion on Therapeutic Patents 31 (1), 91-106, 2021
182021
Development of novel ruthenium (ii)–arene complexes displaying potent anticancer effects in glioblastoma cells
P Kumar, I Mondal, R Kulshreshtha, AK Patra
Dalton Transactions 49 (38), 13294-13310, 2020
172020
MicroRNA therapeutics in glioblastoma: Candidates and targeting strategies
I Mondal, S Sharma, R Kulshreshtha
AGO-Driven Non-Coding RNAs, 261-292, 2019
112019
TiO2 nanoparticles as exogenous contrast agent for 1 µm swept source optical coherence tomography: an in vitro study
A Kumar, I Mondal, P Roy, R Poddar
Laser Physics 28 (3), 035601, 2018
102018
Engineered smart materials for RNA based molecular therapy to treat Glioblastoma
RR Singh, I Mondal, T Janjua, A Popat, R Kulshreshtha
Bioactive Materials 33, 396-423, 2023
52023
Coagulation profile in patients suffering from acute brucellosis
I Mondal, S Sanyal, S Das
Asian J Pharm Clin Res 6, 179-80, 2013
32013
Hyphenation of lipophilic ruthenium (ii)-diphosphine core with 5-fluorouracil: an effective metallodrug against glioblastoma brain cancer cells
A Saha, I Mondal, A Kumari, AK Sonkar, R Mishra, R Kulshreshtha, ...
Dalton Transactions 53 (4), 1551-1567, 2024
22024
Transglutaminase-Polyethyleneimine Nanoflowers Mediated Cellular Delivery of Anti-miR-210 for Effective Glioblastoma Therapy
I Mondal, SW Fatima, S Priya, S Sengupta, SK Khare, R Kulshreshtha
ACS Biomaterials Science & Engineering 9 (5), 2558-2571, 2023
22023
系统目前无法执行此操作,请稍后再试。
文章 1–9